Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Norway / NCT06315075
Recruiting Not applicable

Dialectical Behavior Therapy for Adolescents With Self-harm and Suicidal Behavior- an Open Trial

NCT06315075 · tracked via the Priya Life Science Norway tracker
Phase
Not applicable
Started
2024-01-15
Last updated
2026-08-31

Condition(s) studied

Self-harmSuicidal IdeationSuicide and Self-harm

Investigational drug(s) / intervention(s)

Dialectical behavior therapy for adolescents (DBT-A)

Dialectical behavior therapy for adolescents (DBT-A): A 20-week DBT-A with a weekly individual session (45 minutes), a weekly session of multifamily skills training groups with a caregiver (120 minutes), and telephone consultation with individual therapists outside therapy sessions as needed. The treatment consists of four components and is delivered according to the manual except for the phone coaching that PBU offers workdays until 8 pm.

Study summary

The goal of this pre-post-follow-up study is to examine how well the treatment Dialectical behavior therapy for adolescents (DBT-A) with a duration of 20 weeks for adolescents with self-harm and suicidal behavior works in routine clinical practice. The main questions it aims to answer are:

* to investigate how well DBT-A works after treatment and at 3-month follow-up, measured by episodes of self-harm, suicide attempts, depressive symptoms and quality of life, drop-out from treatment and number of possible participants who decline DBT-A.
* to investigate how well DBT-A works at 12 months follow-up
* to investigate whether pre-treatment factors can predict who will benefit from treatment

Eligibility

Sex
ALL
Min age
13 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Age 13-18 years * Ongoing or a history of self-harm the last six months; current suicidal behavior (suicidal thoughts or at least one suicide attempt within the previous six months); at least three criteria of Diagnostic and Statistical Manual -5 (DSM-5) Borderline personality disorder (BPD), or the self-destruction criterion of DSM-5 BPD in addition to minimum two subthreshold criteria as assessed by the Structured Clinical Interview for DSM-5 Personality Disorders (SCID-5-PD) (First et al., 2016) * Fluency in Norwegian * One parent/trusted adult that can participate together with the adolescent. Exclusion Criteria: * Intellectual disability * Significant learning or language impairments * Autism spectrum disorder * Anorexia Nervosa * Any psychotic disorder * Substance abuse disorder. These patients will be offered treatment as usual at their local outpatient clinic.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Dept. of child and adolescent psychiatry, Haukeland University Hospital Bergen Bergen Recruiting

More Haukeland University Hospital trials in Norway

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06315075 on ClinicalTrials.gov ↗ ← All trials in Norway